1. |
2. |
3. |
4. |
5. |
6. |
7. |
8. Sodobna dognanja : 8. šola o ginekološkem raku2024, ni določena Povzetek: Raki rodil predstavljajo pomemben zdravstveni izziv za ženske po vsem svetu. So raznovrstna skupina bolezni katere preživetje se močno razlikuje glede na prizadetost organa, razširjenost
bolezni, odgovora na zdravljenje in psihofizičnega stanja bolnice.
V zadnjih letih smo priča izjemnim napredkom na področju medicinske obravnave in zdravstvenih raziskav, ki so privedla do bistvenih izboljšav pri obravnavi bolnic z ginekološkim rakom. Sodobne metode zdravljenja ne le povečujejo možnosti za preživetje, temveč bistveno prispevajo k višji kakovosti življenja onkoloških bolnic. Z vlaganjem v raziskave in izobraževanje lahko dosežemo nove preboje, ki bodo koristili prihodnjim generacijam žensk.
Ključne besede: ginekologija, onkologija, ginekološka onkologija, zdravljenje, ginekološka kirurgija, radioterapija, imunoterapija, laserska terapija, plodnost, parenteralna prehrana, zborniki, elektronske knjige
Objavljeno v DiRROS: 05.09.2024; Ogledov: 141; Prenosov: 68
 Celotno besedilo (1,37 MB)
Gradivo ima več datotek! Več... |
9. Imunohistokemična analiza izražanja glukokortikoidnih receptorjev pri zgodnjem raku dojk in njihov vpliv na odgovor na zdravljenje z neoadjuvantno sistemsko terapijoMarjetka Sraka, Barbara Gazić, Primož Drev, Cvetka Grašič-Kuhar, 2024, izvirni znanstveni članek Povzetek: Glukokortikoidni receptor (GR) je različno izražen na tumorskih in imunskih celicah raka dojk, njegova izraženost pa je morda odvisna od molekularnega podtipa raka dojk, prav tako njegova izraženost morda vpliva na odgovor na neoad-juvantno sistemsko terapijo. Naš namen je vpeljati zanesljivo imunohistokemično barvanje s protitelesi proti GR, drugi namen pa je oceniti izraženost GR na vzorcih raka dojk in preučiti, ali se ta izraža različno pri različnih podtipih in ali njegova izraženost vpliva na odgovor na neoadjuvantno sistemsko terapijo.
Ključne besede: rak dojk, neoadjuvantno sistemsko zdravljenje, glukokortikoidni receptor
Objavljeno v DiRROS: 26.07.2024; Ogledov: 282; Prenosov: 134
Celotno besedilo (7,50 MB) |
10. Association of OPRM1, MIR23B, and MIR107 genetic variability with acute pain, chronic pain and adverse effects after postoperative tramadol and paracetamol treatment in breast cancerZala Vidic, Katja Goričar, Branka Stražišar, Nikola Bešić, Vita Dolžan, 2023, izvirni znanstveni članek Povzetek: Background. Tramadol is an opioid analgesic often used for pain management after breast cancer surgery. Its anal-gesic activity is due to the activation of the μ-opioid receptor, encoded by the OPRM1 gene. This study investigated the association of genetic variability in OPRM1 and its regulatory miRNA genes with outcomes of tramadol/paraceta-mol treatment after breast cancer surgery with axillary lymphadenectomy.Patients and methods. The study included 113 breast cancer patients after breast cancer surgery with axillary lymphadenectomy treated with either 75/650 mg or 37.5/325 mg of tramadol with paracetamol for pain relief within the randomized clinical trial KCT 04/2015-DORETAonko/si at the Institute of Oncology Ljubljana. All patients were geno-typed for OPRM1 rs1799971 and rs677830, MIR23B rs1011784, and MIR107 rs2296616 using competitive allele-specific PCR. The association of genetic factors with acute and chronic pain as well as adverse effects of tramadol treatment was evaluated using logistic regression, Fisher’s exact test, and Mann-Whitney test.Results.The investigated OPRM1 related polymorphisms were not associated with acute pain assessed with the VAS scale within four weeks after surgery (all P > 0.05). Carriers of at least one polymorphic OPRM1 rs1799971 allele had a higher risk of constipation in the first four weeks after surgery compared to non-carriers (OR = 4.5, 95% CI = 1.6–12.64, P = 0.004). Carriers of at least one polymorphic OPRM1 rs677830 allele had a higher risk of constipation after third week of tramadol treatment (OR = 3.11, 95% CI = 1.08–8.89, P = 0.035). Furthermore, carriers of two polymorphic MIR23Brs1011784 alleles had a higher risk of nausea after 28 days of tramadol treatment (OR = 7.35, 95% CI = 1.27–42.6, P = 0.026), while heterozygotes for MIR107 rs2296616 allele had a lower risk of nausea after 21 days of tramadol treatment (OR = 0.21, 95% CI = 0.05–0.87, P = 0.031). In carriers of two polymorphic MIR107 rs2296616 alleles, chronic pain was significantly more common than in carriers of two wild-type alleles (P = 0.004). Carriers of at least one polymorphic MIR23B rs1011784 allele experienced more neuropathic pain after adjustment for tramadol dose (OR = 2.85, 95% CI = 1.07–7.59, P = 0.036), while carriers of at least one polymorphic OPRM1 rs677830 allele experienced less neuropathic pain compared to carriers of two wild-type alleles (OR = 0.38, 95% CI = 0.15–0.99, P = 0.047).Conclusions.Genetic variability of OPRM1 and genes coding for miRNAs that could affect OPRM1 expression may be associated with adverse effects of tramadol/paracetamol treatment as well as with chronic and neuropathic pain after breast cancer surgery with axillary lymphadenectomy.
Ključne besede: operacija raka na dojki, zdravljenje bolečine, tramadol
Objavljeno v DiRROS: 25.07.2024; Ogledov: 770; Prenosov: 191
Celotno besedilo (1,48 MB)
Gradivo ima več datotek! Več... |
